Preliminary results of a phase I trial inspire the phase II KarMMa study of bb2121, an anti-B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T Cell therapy, for relapsed and refractory Multiple Myeloma (rrMM)

被引：0
|
作者：
Einsele, H. [1 ]
Goldschmidt, H. [2 ]
Weisel, K. [3 ]
Hege, K. [4 ]
Munshi, N. [5 ]
San Miguel, J. [6 ]
机构：
[1] Univ Clin Wuerzburg, Wurzburg, Germany
[2] Univ Clin Heidelberg, Heidelberg, Germany
[3] Univ Clin Tuebingen, Tubingen, Germany
[4] Celgene Corp, San Francisco, CA USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Clin Univ Navarra, Pamplona, Spain
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V409
引用
收藏
页码：134 / 134
页数：1
相关论文
共 50 条
  • [31] PHASE I, OPEN-LABEL TRIAL OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Zhang, W.
    Zhao, W.
    Liu, J.
    He, A.
    Chen, Y.
    Cao, X.
    Yang, N.
    Wang, B.
    Zhang, P.
    Zhang, Y.
    Wang, F.
    Lei, B.
    Gu, L.
    Yang, Y.
    Bai, J.
    Zhang, R.
    Wang, X.
    Ma, X.
    Wang, J.
    Wang, J.
    Wei, L.
    Zhang, J.
    Zang, X.
    Zhuang, Q.
    Fan, F. X.
    HAEMATOLOGICA, 2017, 102 : 2 - 3
  • [32] Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial
    Shah, Nina
    Munshi, Nikhil C.
    Berdeja, Jesus G.
    Jagannath, Sundar
    Finney, Olivia
    Martin, Nathan
    Agarwal, Amit
    Rowe, Everton
    Campbe, Timothy B.
    San-Miguel, Jesus F.
    BLOOD, 2021, 138
  • [33] Clinical remissions and limited toxicity in a first-in-human multicenter study of bb2121, a novel anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma
    Berdeja, J. G.
    Lin, Y.
    Raje, N.
    Siegel, D.
    Munshi, N.
    Turka, A.
    Lam, L. P.
    Quigley, M. T.
    Kochenderfer, J. N.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S5 - S5
  • [34] KarMMa Subanalysis: Correlation of Baseline Characteristics with Complete Response (CR) to Idecabtagene vicleucel (Ide-Cel, bb2121), a BCMA-Targeted CAR-T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
    Einsele, H.
    Shah, N.
    Munshi, N.
    Berdeja, J.
    Jagannath, S.
    Finney, O.
    Martin, N.
    Agarwal, A.
    Rowe, E.
    Campbell, T. B.
    San-Miguel, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 248 - 248
  • [35] Early MRD negativity to predict deepening myeloma response in relapsed/refractory multiple myeloma (RRMM) patients treated with bb2121 anti-BCMA CAR T cells.
    Munshi, Nikhil C.
    Berdeja, Jesus G.
    Lin, Yi
    Kochenderfer, James
    Raje, Noopur S.
    Liedtke, Michaela
    Jagannath, Sundar
    Madduri, Deepu
    Rosenblatt, Jacalyn
    Maus, Marcela Valderrama
    Turka, Ashley
    Lam, Lyh Ping
    Hege, Kristen
    Campbell, Timothy Brandon
    Massaro, Monica
    Petrocca, Fabio
    Siegel, David Samuel DiCapua
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study.
    Manier, Salomon
    Kansagra, Ankit J.
    Anderson, Larry D., Jr.
    Berdeja, Jesus G.
    Jagannath, Sundar
    Lin, Yi
    Lonial, Sagar
    Shah, Nina
    Raje, Noopur S.
    Siegel, David Samuel DiCapua
    Oriol, Albert
    Truppel-Hartmann, Anna
    Rowe, Everton
    Patel, Payal
    Agarwal, Amit
    Campbell, Timothy B.
    Rodriguez-Otero, Paula
    Munshi, Nikhil C.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] Clinical activity of P-BCMA-ALLO1, a B-cell maturation antigen (BCMA) targeted allogeneic chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed refractory multiple myeloma (RRMM) patients (pts) following progression on prior BCMA targeting therapy
    Dholaria, Bhagirathbhai
    Shune, Leyla
    Kin, Andrew
    McArthur, Katherine
    Eskew, Jeff D.
    Martin, Christopher E.
    Haag, Sabrina
    McCaigue, Joanne
    Namini, Hamid
    DePrimo, Sam
    Cranert, Stacey
    Coronella, Julia
    Shedlock, Devon
    Belani, Rajesh
    CANCER RESEARCH, 2024, 84 (07)
  • [38] KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
    Raje, Noopur S.
    Berdeja, Jesus G.
    Rodriguez-Otero, Paula
    Green, Damian J.
    Jagannath, Sundar
    Lonial, Sagar
    Gipson, Adrianna
    Caia, Andrea
    Martin, Nathan
    Yang, Zhihong
    Pittari, Gianfranco
    Mateos, Maria-Victoria
    BLOOD, 2021, 138
  • [39] The BCMA CAR T cell therapy idecabtagene vicleucel (ide-cel/bb2121) in relapsed and refractory multiple myeloma (RRMM): outcomes from phase 1 study support the phase 3 KarMMa-3 study design to compare ide-cel versus standard triplet regimens
    Einsele, H.
    Raab, M.
    Kroeger, N.
    Fenk, R.
    Scheid, C.
    Munshi, N.
    Petrocca, F.
    Hege, K.
    Novick, S.
    Raje, N.
    Kochenderfer, J. N.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 140 - 141
  • [40] Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
    Shi, Ming
    Wang, Jiaojiao
    Huang, Hongming
    Liu, Dan
    Cheng, Hai
    Wang, Xu
    Chen, Wei
    Yan, Zhiling
    Sang, Wei
    Qi, Kunming
    Li, Depeng
    Zhu, Feng
    Li, Zhenyu
    Qiao, Jianlin
    Wu, Qingyun
    Zeng, Lingyu
    Fei, Xiaoming
    Gu, Weiying
    Miao, Yuqing
    Xu, Kailin
    Zheng, Junnian
    Cao, Jiang
    NATURE COMMUNICATIONS, 2024, 15 (01)
12345